Chemical Compound

Sulbutiamine

isobutyrylthiamine disulfide

Evidence TierDWADA NOT PROHIBITED

tuneTypical Dose

400 mg/day. 600 mg/day only in short-term subgroup context

watchEffect Window

Days to weeks

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Sulbutiamine is a synthetic, fat-soluble derivative of vitamin B1 designed for higher tissue penetration. It is used for fatigue and subjective cognitive energy complaints, with limited controlled trial support.

Some studies, including in asthenia, report improved fatigue and mood measures, plausibly through thiamine-related energy and neurotransmitter effects. Benefits may be more noticeable in fatigue states. Minority evidence explores sexual function and neuropathy outcomes with limited data. Tolerance and diminishing perceived effects can occur with frequent use, and overall evidence remains modest.

Thiamine derivative with hypothesized CNS/metabolic support. Limited clinical confirmation.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Day 28 fatigue outcomes in CPIF
  • Nerve conduction changes in diabetes (exploratory)

Secondary Outcomes

  • Transient symptom signal in subgroup at day 7
  • No durable overall fatigue superiority in large CPIF trial

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy/lactation
  • Severe psychiatric instability

Side effects

  • Headache
  • Sleep changes
  • GI discomfort

Interactions

  • Anxiety-activating agents

Avoid if

  • No objective benefit at 2-4 weeks

Evidence

Study-level References

sulbutiamine-SRC-001Randomized, double-blind, placebo-controlled trial
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/10573727/ doi:10.1016/s0248-8663(00)80096-x

Population: Adults with chronic postinfectious fatigue (n=326)

Dose protocol: 400 mg/day vs 600 mg/day vs placebo for 28 days

Key findings: No significant overall group difference at day 28. Early day-7 subgroup signal in women on 600 mg/day.

Notes: Effect was not durable and requires replication.

Paper content

No significant overall group difference at day 28; early day-7 subgroup signal in women on 600 mg/day.

sulbutiamine-SRC-002Open randomized controlled study
Sourceopen_in_new

https://pubmed.ncbi.nlm.nih.gov/22969314/ (PMID: 22969314; full-text archive: https://pmc.ncbi.nlm.nih.gov/articles/PMC3436103/)

Population: Type 2 diabetic patients with peripheral neuropathy (n=30)

Dose protocol: 400 mg/day for 6 weeks

Key findings: Improvement in nerve conduction metrics and signs. Symptom scales improved less consistently.

Notes: Small sample and open design limit certainty.

Paper content

Improvement in nerve conduction metrics and signs; symptom scales improved less consistently.

sulbutiamine-SRC-003Narrative synthesis/review
Sourceopen_in_new

https://pmc.ncbi.nlm.nih.gov/articles/PMC7210561/

Population: Multiple small historical cohorts

Dose protocol: 100-600 mg ranges reported across trials

Key findings: Broad positive claims not matched by standardized evidence.

Notes: Use as background context only, not primary efficacy evidence.

Paper content

Broad positive claims not matched by standardized evidence.

sulbutiamine-SRC-004Narrative review.
Sourceopen_in_new

Bykov YV, Bekker RA. On the specific treatment of asthenic states: focus on sulbutiamine. Ter Arkh. 2022;94(5). doi:10.26442/00403660.2022.05.201533. PMID:36286970.

Population: Review covering clinical evidence for sulbutiamine in asthenic states across multiple studies.

Dose protocol: Various dosing regimens reviewed for asthenia

Key findings: Narrative review concluding high efficacy and safety for asthenia. Claims of superiority over alternatives not supported by rigorous head-to-head trials.

Notes: Russian-language narrative review. Useful as a summary of the sulbutiamine clinical landscape but does not elevate the evidence grade.

Paper content

This 2022 review examined the pharmacokinetics, pharmacodynamics, and clinical evidence for sulbutiamine in the treatment of asthenic states. The authors concluded that sulbutiamine demonstrated high efficacy and safety for asthenia. However, the review must be interpreted cautiously. It is published in a Russian-language journal, it is narrative rather than systematic, and its conclusions about superiority over alternatives are not supported by large, well-controlled comparative trials in the Western literature. The review is useful as a summary of the existing sulbutiamine clinical landscape but does not change the overall low-confidence evidence grade for this compound.

Guides

Setup

Help